Rocket Pharmaceuticals, Inc.
RCKT
$3.21
$0.123.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 24.56% | 1.04% | 1.16% | -1.12% | -7.79% |
| Total Depreciation and Amortization | 35.62% | 8.77% | 32.61% | 22.02% | 35.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.21% | 39.26% | -4.10% | 80.80% | 4.02% |
| Change in Net Operating Assets | -491.81% | 20.53% | -0.64% | -103.28% | 149.33% |
| Cash from Operations | 3.23% | 9.03% | 1.87% | -60.00% | 8.83% |
| Capital Expenditure | 103.40% | 97.41% | 82.11% | 93.35% | 65.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.22% | -44.73% | -255.58% | 72.41% | 52.16% |
| Cash from Investing | 18.62% | -42.90% | -265.65% | 73.10% | 63.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 46,664.45% | -99.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -138.07% | -85.95% | -- | 46,664.45% | -99.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 59.78% | -610.00% | -451.53% | 157.75% | -85.05% |